

Oregon Prescription Drug Monitoring Program 2019 2nd Quarter Report


Percentage change evaluated relative to 2nd Quarter, 2018

healthoregon.org/pdmp



Summary

- Registration has increased over last year in all prescriber types (MD/PA/DO, 26.8%; NP, 24.3%; DDS/DMD, 51.8%; ND, 20.2%), pharmacists (17.9%) and delegates (52.2%)(Table 4). New registration continues among prescribers and pharmacists, likely driven by health systems’ registration efforts prior to PDMP integration.
- AWARe web portal queries (Table 1), as well as integrated queries through the Emergency Department Information Exchange (EDIE), hospitals, clinics and pharmacies (Figure 1) have increased over the last year.
- The number of active users of the PDMP through the web portal has increased among all prescriber types (MD/PA/DO, 0.7%; NP, 4.9%; DDS/DMD, 15.9%; ND, 11%), pharmacists (0.7%) and delegates (24.9%) (Table 4).
- Prescriptions for opioids continued to trend downward (Hydrocodone, - 8.7%; Oxycodone, - 5.8%), while stimulants have increased (Amphetamine, + 19.6%; Methylphenidate, + 4.2%) (Table 5).
- Prescriptions have increased for buprenorphine (+ 85.6%) and naloxone (+ 73.2%), but have decreased for buprenorphine/naloxone combinations (- 6.2%) (Table 6).



† Query data drawn from Apriss AWARe for back compatibility with past reporting. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2019 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2018

healthoregon.org/pdmp



Table 1. Pharmacy Reporting: April - June, 2019

Measure	Percent
Reporting	99.3 %
Reporting on time	96.3 %

- Average monthly reporting by pharmacies is consistently high (99.3%).
- The vast majority of pharmacies reporting are submitting data in a timely fashion (96.3%)

Table 2. Web Portal Summary Statistics: April - June, 2019

Measure	Count	% Change*
Queries †	385,337	+ 1.2 %
Healthcare providers	93,930	+ 2.6 %
Pharmacies	113,521	- 18.5 %
Delegates	177,697	+ 20.0 %

- Web portal queries have increased by 1.2% over the same quarter last year.
- Growth in queries is greatest among delegates (20%) followed by health care providers (2.6%).
- Querying activity by pharmacists has declined (18.5%).
- Slowed growth and contraction in these numbers may reflect the expansion of PDMP integration and increasing use of integrated query through health information technology (HIT) by prescribers and pharmacists in Oregon (Figure 1).

Table 3. Special Requests: April - June, 2019

Measure	Count
Special Requests Total	122
Patient Records	19
Healthcare Board	86
Law Enforcement	17

- 122 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests followed by patients and law enforcement.

* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxRxE for back compatibility with past reporting.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2019 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2018

healthoregon.org/pdmp



Table 4. PDMP Enrollment and System Use: April - June, 2019

	Prescribers	Enrolled	Queried
All Prescribers	17,247	14,571 / 84.5%	8,088 / 55.5%
Top 4K Prescribers	4,000	3,776 / 94.4%	2,941 / 77.9%
Top 2K Prescribers	2,000	1,926 / 96.3%	1,612 / 83.7%

- During the 2nd quarter of 2019 there were 17,247 prescribers who wrote prescriptions for controlled substances in Oregon.
- Registration for the PDMP has increased among all prescribers and especially among frequent prescribers reflecting the impact of mandatory registration.
- In quarter two 55.5% of enrolled prescribers queried the system; 77.9% of the top 4,000 prescribers; 83.8% of the top 2,000 prescribers.

Table 5. PDMP Query by User Group: April - June, 2019

Discipline	Total User Accounts	% Change*	Active Users \pm †	% Change*	Average Queries per User \pm †
MD/PA/DO	16,890	+ 26.8%	2,817	+ 0.7%	138
Delegates	4,657	+ 52.2%	2,646	+ 24.9%	356
NP/CNS-PP	3,437	+ 24.3%	1,068	+ 4.9%	152
RPh	3,363	+ 17.9%	1,898	+ 0.7%	403
DDS/DMD	2,714	+ 51.8%	505	+ 15.8%	40
ND	524	+ 20.2%	161	+ 11.0%	61

- PDMP registration has increased among all prescriber groups, pharmacists and delegates.
- The number of registered users actively querying the PDMP through the web portal increased relative to the same quarter last year.
- Patterns of registration and use are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.

* Percentage change figures evaluated relative to the same time period during the prior year.

\pm Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxRxE for back compatibility with past reporting.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program
2019 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2018

healthoregon.org/pdmp



Table 6. Top Prescriptions: April - June, 2019

Drug	# of Rx	% of all Rx	% Change*
All	1,483,312	100%	- 1.2%
Hydrocodone	268,325	18.1%	- 8.7%
Oxycodone	230,759	15.6%	- 5.8%
Amphetamine	152,634	10.3%	+ 19.6%
Tramadol	86,626	5.8%	- 2.5%
Lorazepam	82,277	5.5%	- 5.6%
Pseudoephedrine	81,658	5.5%	+ 14.3%
Zolpidem	74,853	5.0%	- 8.4%
Methylphenidate	70,562	4.8%	+ 4.2%
Alprazolam	65,706	4.4%	- 5.0%
Clonazepam	62,681	4.2%	- 4.1%

- The number of prescriptions for opioid and benzodiazepine medications continues to decrease relative to the same quarter last year.
- Prescriptions for stimulants, including amphetamine, methylphenidate and pseudoephedrine, increased relative to the same quarter last year.

Table 7. Prescriptions for Buprenorphine and Naloxone: April - June, 2019

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	25,655	1.7%	+ 85.6%
Buprenorphine/Naloxone	24,784	1.7%	- 6.2%
Naloxone	3,090	0.2%	+ 73.2%

- Prescriptions for buprenorphine and naloxone have increased while prescriptions for buprenorphine/naloxone combinations have decreased relative to the same quarter last year.
- The apparent growing number of naloxone prescriptions may reflect increased reporting by pharmacies or an increase in naloxone co-prescription by clinicians or pharmacists.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

* Percentage change figures evaluated relative to the same time period during the prior year